Clinical trial
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients…
NCT00426127 · University of Iowa, Other · Terminated
Key facts
| NCT number | NCT00426127 |
|---|---|
| Title | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer |
| Official title | Phase II Trial of Docetaxel and Liposomal Doxorubicin (Doxil) Chemotherapy Combined With Enoxaparin in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | University of Iowa, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Liposomal Doxorubicin, Enoxaparin |
| Enrollment | 2 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jan 24, 2007 |
| Last update posted | Dec 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: